FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes

Brain

Volumn 127, Issue 10, 2004, Pages 2331-2338

  Younes Mhenni, S ^a   Janier, M F ^b   Cinotti, L ^b   Antoine, J C ^c   Tronc, F ^d   Cottin, V ^d   Ternamian, P J ^d   Trouillas, P ^a   Honnorat, J ^a,e  

^a UNIVERSITÉ LYON 1   (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c SERVICE DE NEUROLOGIE   (France)

^d LOUIS PRADEL HOSPITAL   (France)

^e HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Cancer; Paraneoplastic antibodies; Paraneoplastic neurological syndromes; Whole body PET scan

Indexed keywords

AMPHIPHYSIN ANTIBODY; CV2 ANTIBODY; FLUORODEOXYGLUCOSE F 18; HU ANTIBODY; PROTEIN ANTIBODY; RI ANTIBODY; UNCLASSIFIED DRUG; YO ANTIBODY; CANCER ANTIBODY; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AXILLARY LYMPH NODE; BREAST; BREAST ADENOCARCINOMA; CARCINOMATOUS PERITONITIS; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM; NEUROLOGIC DISEASE; OVARY CARCINOMA; PARANEOPLASTIC NEUROPATHY; PAROTID GLAND; PATIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROSPECTIVE STUDY; RADIOISOTOPE DISTRIBUTION; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; THYMOMA; TRANSPORT KINETICS; TUMOR DIAGNOSIS; ADENOCARCINOMA; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; MEDIASTINUM TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SCINTISCANNING; SMALL CELL CARCINOMA; WHOLE BODY COUNTING;

ADENOCARCINOMA; AGED; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 4944227639     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh247     Document Type: Article

References (22)

1. Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol 1999; 26: 577-83.
2. 18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000; 48: 105-8.
3. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2: 157-64.
4. Chartrand-Lefebvre C, Howarth HN, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR Am J Roentgenol 1998; 170: 1513-7.
5. Coates G, Skehan SJ. Emerging role of PET in the diagnosis and staging of lung cancer. Can Respir J 1999; 6: 145-52.
6. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71: 59-72.
7. Gill S, Murray N, Dalmau J, Thiessen B. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can J Neurol Sci 2003; 30: 269-71.
8. Goerres GW, Michel SC, Fehr MK, Kaim AH, Steinert HC, Seifert B, et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13: 1635-44.
9. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-48.
10. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61: 270-8.
11. Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-82.
12. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109: 982-8.
13. Luchinetti CF, Kimmel DW, Lennon V. Paraneoplastic and oncologic profiles of patients seropositive for type l antineuronal nuclear autoantibodies. Neurology 1998; 50: 652-7.
14. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenice syndrome. Brain 1997; 120: 1279-300.
15. Molinuevo JL, Graus F, Serrano C, Rene R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998; 44: 976-80.
16. Moog F, Barngerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole body 2-deoxy-2[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
17. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter G, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254-61.
18. Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001; 124: 2223-31.
19. Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000, 55: 713-15.
20. Shinohara Y, Ohnuki Y, Yoshii F, Takahashi W, Onoe K, Takagi S. Detection of primary tumor in paraneoplastic cerebellar degeneration by FDG-PET. Ann Neurol 1998; 43: 684.
21. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG; PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22: 277-85.
22. Wittram C, Fischman AJ, Mark E, Ko J, Shepard JA. Thymic enlargement and FDG uptake in three patients: CT and FDG positron emission tomography correlated with pathology. AJR Am J Roentgenol 2003; 180: 519-22.